- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Starpharma Holdings Limited (ASX:SPL, USOTC:SPHRY) announced today that its company information has been made available in Standard & Poor's Corporation Records Listing Program. As part of the S&P program, a full description of Starpharma Holdings has been published in the Daily News Section of Standard Corporation Records, a recognized securities manual for secondary trading in approximately 38 US states under their Blue Sky Laws. Standard Corporation Records is available in print, CD-ROM, and via the Web at
http://www.netadvantage.com, as well as through numerous electronic vendors.
The company information about Starpharma Holdings to be made available through this program includes an in-depth description of Starpharma's business operations, share price, dividend history, shares outstanding, company financial position, earnings, and a full income statement and balance sheet.
SPHRY: Starpharma's American Depositary Receipts (ADRs) trade under the code SPHRY (CUSIP number 855563102). Each Starpharma ADR is equivalent to 10 ordinary shares of Starpharma as traded on the Australian Stock Exchange. The Bank of New York is the depositary bank. The ADR program was launched in January 2005 and ADRs now represent 10.2% of issued capital. Starpharma's participation in Standard & Poor's Records Listing Program will allow brokerage and investment firms to actively promote SPHRY in as
many as 38 US states, further increasing liquidity. Without coverage such as that provided by this program, under state securities or "blue sky" laws, brokers would only be permitted to respond to calls from investors. The listing is also a part of the process that will qualify SHPRY for participation in the new OTCQX International Prime program, which is due to commence shortly. OTCQX is intended to enhance the trading range of qualified international issuers from among the thousands of securities electronically traded on the OTC markets. Starpharma's ADR program is managed by The Bank of New York and traded by major brokers including Merrill Lynch, Credit Lyonnais, Natexis Bleichroeder, and Pershing LLC. Three further broking firms are expected to be added as Market Makers in SPHRY over the coming weeks. Company information distributed through the Corporation Records Program is based upon information that Standard & Poor's considers to be reliable, but neither Standard & Poor's nor its affiliates warrant its completeness or accuracy, and it should not be relied upon as such. This material is not intended as an offer or solicitation for the purchase or sale of any security
Starpharma Holdings Limited (ASX:SPL, USOTC:SPHRY) is a world leader in the development of dendrimer nanotechnology for pharmaceutical, life-science and other applications. SPL is principally composed of two operating companies, Starpharma Pty Ltd in Melbourne, Australia and Dendritic Nanotechnologies, Inc in Michigan, USA. Products based on SPL’s dendrimer technology are already on the market in the form of diagnostic elements and laboratory reagents. The Company’s lead pharmaceutical development product is VivaGel™ (SPL7013 Gel), a vaginal microbicide designed to prevent the transmission of STIs, including HIV and genital herpes, and currently in clinical trials. The Company’s other lead product is PrioFect™, a new application of dendrimer technology. PrioFectTM is a transfection agent with applications including siRNA (small interfering RNA) transfection. In February 2007 PrioFect™ was licensed for non-therapeutic applications to EMD Biosciences, part of Merck KGaA’s Performance and Life Science Chemicals division. More broadly the company is actively exploring dendrimer opportunities in areas such as Drug Delivery, Targeted Diagnostics and in materials science applications such as adhesives, lubricants and water remediation. SPL has a comprehensive IP portfolio that comprises more than 180 patents/applications issued and pending across 32 patent families - a unique level of IP concentration among nanotechnology companies.
For more information, please click here
Tel: +61 2 9237 2800
Mob: +61 417 382 391
Dr Jackie Fairley
Chief Executive Officer
+61 3 8532 2704
+61 3 8532 2702
Standard & Poor’s
Media relations contact:
Copyright © Starpharma Holdings LimitedIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
Forge Nano raises $20 million in Series A Funding: Nano coating technology innovator Forge Nano will use funding to expand manufacturing capacity and grow Lithium-Ion battery opportunities November 3rd, 2016
UTSA study describes new minimally invasive device to treat cancer and other illnesses: Medicine diffusion capsule could locally treat multiple ailments and diseases over several weeks December 3rd, 2016
Novel Electrode Structure Provides New Promise for Lithium-Sulfur Batteries December 3rd, 2016